JunB and PTEN in prostate cancer: 'loss is nothing else than change'.

about

MicroRNA and Transcription Factor Gene Regulatory Network Analysis Reveals Key Regulatory Elements Associated with Prostate Cancer Progression.A Network-Based Integrative Workflow to Unravel Mechanisms Underlying Disease Progression.

P2860

Q36231493-076F0E30-CBC6-403E-8C56-68F15CCF201D Q46734695-CDBA9429-DF1F-4191-BAF8-CDFC7CB6A5A0

P2860

JunB and PTEN in prostate cancer: 'loss is nothing else than change'.

Item

http://www.wikidata.org/entity/Q42558175

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

JunB and PTEN in prostate cancer: 'loss is nothing else than change'.

@en

JunB and PTEN in prostate cancer: 'loss is nothing else than change'.

@nl

type

Item

label

JunB and PTEN in prostate cancer: 'loss is nothing else than change'.

@en

JunB and PTEN in prostate cancer: 'loss is nothing else than change'.

@nl

prefLabel

JunB and PTEN in prostate cancer: 'loss is nothing else than change'.

@en

JunB and PTEN in prostate cancer: 'loss is nothing else than change'.

@nl

P1476

JunB and PTEN in prostate cancer: 'loss is nothing else than change'.

@en

P2093

P Birner

http://www.w3.org/2001/XMLSchema#string

P2860

c-JUN prevents methylation of p16(INK4a) (and Cdk6): the villain turned bodyguard

Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis

Common features of chromatin in aging and cancer: cause or coincidence?

Genetically engineered mouse models of prostate cancer

Signal transduction by the JNK group of MAP kinases

Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis

Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer

The role of c-Jun and c-Fos expression in androgen-independent prostate cancer.

Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer.

Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer.

P2888

cdd.2014.232

P304

522-523

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1038/CDD.2014.232

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Lukas Kenner

Olaf Merkel

Gerda Egger

P577

2015-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273325980

http://www.w3.org/2001/XMLSchema#string

P6179

1049219248

http://www.w3.org/2001/XMLSchema#string

P698

25747853

http://www.w3.org/2001/XMLSchema#string

P932

4356347

http://www.w3.org/2001/XMLSchema#string

JunB and PTEN in prostate cancer: 'loss is nothing else than change'.

about

P2860

P2860

JunB and PTEN in prostate cancer: 'loss is nothing else than change'.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P5875

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P5875

P6179

P698

P932